Latest Whitepapers

Now, more than ever, we need to take responsibility for our actions. As global levels of atmospheric CO2 continue to increase, we need to be making positive steps forward to reduce our emissions and remove CO2 from the atmosphere.

The successful use of immunotherapies to help combat cancer has expanded rapidly in the last few years, with many therapies now approved for clinical use.

Download this whitepaper to discover how to overcome the limitations of PCR testing, how RT-qPCR will impact diagnostics both in lab and at point of care and how RT-qPCR is driving new methods and applications.

Download this whitepaper to learn more about mRNA therapeutics including how they could treat genetic diseases and cancer, the challenges associated with delivery and dosage as well as how to avoid an unwanted immune response.

As we have gained a greater understanding of cancer biology, therapeutic interventions have evolved from a one-size-fits-all approach to more targeted approaches, which afford patients not only longer lives but increased quality of life.

Data accessibility has been a challenge, until now. Using data science algorithms, it is now possible to process and integrate all LIMS and enterprise data to provide valuable insights and timely, meaningful recommendations.

In this cell and gene therapy insights expert roundtable, a panel of four experts will answer some central questions surrounding the development of novel biotherapeutics.

The quality of indoor air dramatically affects the health of animals and humans during livestock production. Airborne transmission has been suspected of being responsible for epidemics of highly infectious diseases in livestock production, and due to the COVID-19 pandemic, there has been increasing concern about the role of wild animals in the epidemiology of most zoonoses.

Download this whitepaper to learn how an archive strategy can reduce backup and recovery times whilst removing manual intervention and variability.

Cell-based chimeric antigen receptor (CAR) T-cell therapies have rapidly advanced from preclinical research. This success has driven an influx of companies to further develop CAR T-cell constructs to make them more effective, safe and persistent.